GlassScriptPhysician profile
Roger Frank Johnson
NPI 1780624742
$26,516.49
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $799 · 2021: $3,200 · 2022: $1,039 · 2023: $435 · 2024: $138 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.86 |
| Education | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,542.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,521.26 | 2019 | |
| Intuitive Surgical, INC. | $4,030.70 | 2021-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,290.84 | 2019-2024 | Breztri |
| Bard Access Systems, INC. | $850.21 | 2019 | |
| Pulmonx Corporation | $562.65 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Ethicon INC. | $555.32 | 2019 | |
| Pinnacle Biologics, INC | $195.79 | 2020-2022 | |
| Insmed, INC. | $174.20 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $166.42 | 2019-2025 | Nucala |
| La Jolla Pharmaceutical Company | $150.61 | 2023-2025 | Giapreza, Xerava |
| Auris Health, INC. | $104.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $90.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.45 | 2019 | |
| Merck Sharp & Dohme LLC | $42.97 | 2019-2024 | Keytruda |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.83 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $25.23 | 2019 | |
| Circassia INC. | $23.40 | 2019 | |
| Grifols USA, LLC | $20.33 | 2019 | |
| United Therapeutics Corporation | $17.60 | 2019 | |
| Mylan Specialty L.P. | $17.51 | 2019 | |
| Advanced Respiratory, INC | $14.54 | 2019 | |
| Verona Pharma, INC. | $13.59 | 2025 | Ohtuvayre |
| Pfizer INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.